Search by Drug Name or NDC
NDC 43386-0090-19 GAVILYTE G 236; 2.97; 6.74; 5.86; 22.74 g/274.31g; g/274.31g; g/274.31g; g/274.31g; g/274.31g Details
GAVILYTE G 236; 2.97; 6.74; 5.86; 22.74 g/274.31g; g/274.31g; g/274.31g; g/274.31g; g/274.31g
GAVILYTE G is a ORAL POWDER, FOR SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Lupin Pharmaceuticals,Inc.. The primary component is POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS.
MedlinePlus Drug Summary
Polyethylene glycol-electrolyte solution (PEG-ES) is used to empty the colon (large intestine, bowel) before a colonoscopy (examination of the inside of the colon to check for colon cancer and other abnormalities) or barium enema (a test in which the colon is filled with a fluid and then x-rays are taken) so that the doctor will have a clear view of the walls of the colon. PEG-ES is in a class of medications called osmotic laxatives. It works by causing watery diarrhea so that the stool can be emptied from the colon. The medication also contains electrolytes to prevent dehydration and other serious side effects that may be caused by fluid loss as the colon is emptied.
Related Packages: 43386-0090-19Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Polyethylene glycol-electrolyte solution (PEG-ES)
Product Information
| NDC | 43386-0090 |
|---|---|
| Product ID | 43386-090_cccea25c-6192-418e-a9ee-d97be10e7c69 |
| Associated GPIs | 46992005302130 |
| GCN Sequence Number | 062533 |
| GCN Sequence Number Description | peg3350/sod sulf,bicarb,Cl/KCl SOLN RECON 236-22.74G ORAL |
| HIC3 | D6S |
| HIC3 Description | LAXATIVES AND CATHARTICS |
| GCN | 98308 |
| HICL Sequence Number | 034667 |
| HICL Sequence Number Description | PEG 3350/SOD SULF/SOD BICARB/SOD CHLORIDE/POTASSIUM CHLORIDE |
| Brand/Generic | Generic |
| Proprietary Name | GAVILYTE G |
| Proprietary Name Suffix | TM |
| Non-Proprietary Name | polyethylene glycol-3350 and Electrolytes |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | POWDER, FOR SOLUTION |
| Route | ORAL |
| Active Ingredient Strength | 236; 2.97; 6.74; 5.86; 22.74 |
| Active Ingredient Units | g/274.31g; g/274.31g; g/274.31g; g/274.31g; g/274.31g |
| Substance Name | POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS |
| Labeler Name | Lupin Pharmaceuticals,Inc. |
| Pharmaceutical Class | Increased Large Intestinal Motility [PE], Increased Large Intestinal Motility [PE], Increased Large Intestinal Motility [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhib |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA090231 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 43386-0090-19 (43386009019)
| NDC Package Code | 43386-090-19 |
|---|---|
| Billing NDC | 43386009019 |
| Package | 274.31 g in 1 BOTTLE (43386-090-19) |
| Marketing Start Date | 2009-06-01 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 0.00436 |
| Pricing Unit | ML |
| Effective Date | 2024-02-21 |
| NDC Description | GAVILYTE-G SOLUTION |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1, 5 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |